ArticleBMJ open2024

Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer.

Haiying Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.